Obermeyer Wood Investment Counsel Lllp lowered its stake in shares of Celgene Co. (NASDAQ:CELG) by 8.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,756 shares of the biopharmaceutical company’s stock after selling 28,364 shares during the quarter. Celgene comprises approximately 2.4% of Obermeyer Wood Investment Counsel Lllp’s investment portfolio, making the stock its 23rd biggest position. Obermeyer Wood Investment Counsel Lllp’s holdings in Celgene were worth $28,794,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of CELG. Xact Kapitalforvaltning AB lifted its position in shares of Celgene by 13.4% during the second quarter. Xact Kapitalforvaltning AB now owns 209,138 shares of the biopharmaceutical company’s stock worth $16,610,000 after purchasing an additional 24,765 shares in the last quarter. Welch & Forbes LLC acquired a new stake in shares of Celgene during the second quarter worth about $16,030,000. Viking Fund Management LLC acquired a new stake in shares of Celgene during the second quarter worth about $635,000. Hochman Cole Investment Advisors Inc. lifted its position in shares of Celgene by 38.6% during the second quarter. Hochman Cole Investment Advisors Inc. now owns 6,261 shares of the biopharmaceutical company’s stock worth $497,000 after purchasing an additional 1,744 shares in the last quarter. Finally, Hills Bank & Trust Co. acquired a new stake in shares of Celgene during the second quarter worth about $1,079,000. 73.72% of the stock is currently owned by institutional investors and hedge funds.
CELG stock opened at $70.81 on Wednesday. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. Celgene Co. has a twelve month low of $70.09 and a twelve month high of $110.81. The company has a market cap of $49.66 billion, a price-to-earnings ratio of 10.35, a P/E/G ratio of 0.44 and a beta of 1.53.
CELG has been the topic of several analyst reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a report on Thursday, October 25th. BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a report on Thursday, August 16th. Mizuho reaffirmed a “buy” rating and issued a $129.00 target price on shares of Celgene in a report on Tuesday, July 31st. UBS Group set a $94.00 target price on shares of Celgene and gave the company a “buy” rating in a report on Saturday, October 27th. Finally, Morgan Stanley raised their target price on shares of Celgene from $91.00 to $93.00 and gave the company an “equal weight” rating in a report on Friday, July 27th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $117.91.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/11/14/obermeyer-wood-investment-counsel-lllp-has-28-79-million-position-in-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: Buyback For Investors Defined
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.